Day 1

 
7:30

Registration & Continental Breakfast

8:45

Chairman's Opening Remark's

David Rabuka, Global Head of R & D, Catalent Pharma Solutions

9:00
Optimization of Titers and a Specific Enzyme Conversion Step to Generate Fully Processed Antibody in CHO Cells

Greg Bleck, Ph.D.

Optimization of Titers and a Specific Enzyme Conversion Step to Generate Fully Processed Antibody in CHO Cells

9:30

Celltheon SMART Expression platform for stable long term expression of next generation Biologics and Biosimilar Molecules

Amita Goel, Founder & CEO, Celltheon Corporation

10:00

Switchable Membrane Reporter ( SwiMR) technology for facile bio production and cell line development

Bo Yu, CSO, Larix Biosciences

10:30
To Fucosylate or Not: Utilizing FX knock CHO Lines to Express Fucosylated or Afucosylated Antibodies on Command

SHAHRAM MISAGHI, PHD

To Fucosylate or Not: Utilizing FX knock CHO Lines to Express Fucosylated or Afucosylated Antibodies on Command

Day 2

 
7:30

Continental Breakfast & Networking

8:45

Chairman's Opening Remarks

Dr. Sarfaraz K. Niazi, Ph.D

9:00
Clone Specific improvement in productivity and glycosylation fidelity

Bill Whitford

Clone Specific improvement in productivity and glycosylation fidelity

9:30

Next Generation Monoclonal Antibody Development using Modified Cellular Platform

Dr. Maloy Gosh, Ph.D., CSO, Theramyt Novobiologics

10:00
A New Biobetter Therapeutic - Development & Manufacturing: A Case Study

Dr. Michiel E. Ultee

A New Biobetter Therapeutic - Development & Manufacturing: A Case Study